T
TARGAN
A bio-systems company focused on improving animal health and productivity in the poultry industry
About TARGAN
TARGAN is an animal AgTech company focused on transforming the future of protein production through precision automation. By combining advanced robotics, computer vision, and machine learning, TARGAN has developed scalable solutions that address major inefficiencies in animal agriculture. One of its key technologies is an automated, high-speed vaccine delivery system that enables individualized care for poultry without manual handling, reducing stress on animals while improving health outcomes and productivity. Another breakthrough is its WingScan™ feather sexing technology, which identifies the sex of chicks quickly and accurately, enhancing hatchery efficiency and reducing operational costs.
TARGAN aims to reduce waste, labor intensity, and animal stress while increasing yield and operational efficiency. Their technologies are built for commercial-scale application, making them a strong fit for large producers looking to modernize and future-proof their operations. Beyond poultry, the company is also working to expand its technology platform into swine and aquaculture, bringing data-driven, automated precision to more sectors of the animal protein industry.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Raleigh, United States
- Employees
- 134
- Open positions
- 10
- Dealroom signal
- 87.3/100
- Sub-industry
- AgriTech
- Sector
- Food, Biotechnology, Vaccines, Poultry, Livestock, Core AI, Agricultural Equipment, Biotech and Pharma, Biotechnology in Food
- Technology
- Artificial Intelligence, Machine Learning, Computer Vision
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2026 | $0 | — | Merck Animal Health | ↗ |
| DEBTDebt | Dec 2025 | $100M | — | Symbiotic Capital | ↗ |
Growth signals
Latest recorded traffic for TARGAN is 2.9K monthly website visits, down 46.3% over the last three months. TARGAN's team grew 17.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TARGAN in the Raleigh ecosystem
The TARGAN office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US National Science Foundation
Foundation for Food and Agriculture Research
Series A3 investors entered at this stage
Mountain Group Partners
Merck Animal Health
Oval Park Capital
Series B and later2 investors entered at this stage
NovaQuest Capital Management
Symbiotic Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TARGAN on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TARGAN’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










